Defective in Cullin Neddylation 1 (DCN1) (DCN1)

Defective in Cullin Neddylation 1 (DCN1), also known as DCUN1D1, is a scaffold protein and E3 ligase component that plays a critical role in the neddylation of Cullin proteins, particularly CUL3 (Myles et al., 2025). In the context of erythropoiesis, DCN1 has been identified as a novel upstream regulator of the globin-switching mechanism that controls the transition from fetal to adult hemoglobin (Cellarity, 2025). Inhibition of DCN1 by small molecules, such as the clinical-stage candidate CLY-124, prevents the post-translational modification (neddylation) of the CUL3-containing protein complex (Trenor et al., 2025). This inhibition leads to the robust reactivation of fetal hemoglobin (HbF) production, which can dilute sickle hemoglobin (HbS) and prevent the polymerization and red blood cell sickling characteristic of sickle cell disease (ASH, 2025). Unlike traditional therapies that target DNA or transcription factors directly, DCN1 inhibitors offer a non-cytotoxic oral approach to treating hemoglobinopathies like sickle cell disease and beta-thalassemia (ClinicalTrialsArena, 2025). Preclinical studies have demonstrated that DCN1 inhibition can increase HbF levels above 20% without the dose-limiting toxicities associated with current standards of care (BusinessWire, 2025). This mechanism represents a first-in-class approach to inducing HbF by modulating an upstream regulatory pathway rather than the globin genes themselves.

Other names

DCUN1D1DCNL1SCCRORP42Tes3DCN1-like protein 1

DCN1 inhibition leading to suppression of CUL3 neddylation and subsequent induction of fetal hemoglobin (HbF) production.